logo-loader
Polar Capital Global Healthcare Trust PLC

Polar Cap Glb Health - Net Asset Value(s)

RNS Number : 5243W
Polar Capital Global Health Tst PLC
11 December 2019
 

POLAR CAPITAL GLOBAL HEALTHCARE TRUST PLC ("the Company")

Legal Entity Identifier: 549300YV7J2TWLE7PV84

 

11th December 2019

Net Asset Values

As at close of business on 10th December 2019 the Company's unaudited Net Asset Value, calculated in accordance with the guidelines of the Association of Investment Companies, was:

Ordinary Share (cum income)                                                                   247.08p

 

 

PCGH ZDP PLC

Legal Entity Identifier: 5493004C3YRF9HEVQI09

 

As at close of business on 10th December 2019 the redemption value of the ZDP Shares was:

Zero Dividend Preference (ZDP) Share                                                  107.60p

The Redemption Value of the ZDP Shares compounds annually at 3% and accrues daily, with a redemption value of 122.99p per ZDP Share on 19 June 2024.

 

 

For further information, please call:

Paddy Drewett

Investment Trust Operations Department

Polar Capital Partners Limited

Tel: 020 7227 2700

http://www.polarcapitalhealthcaretrust.com/

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVGGGWCPUPBGUG
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Polar Capital upbeat on the outlook for the healthcare sector

According to James Douglas, fund manager of Polar Capital Global Healthcare Trust PLC (LON:PCGH), the US election isn’t affecting market sentiment in his sector quite as much as it has. Douglas, together with his team reckon valuations for the drug and device makers and care providers remain...

on 23/1/20

2 min read